TY - JOUR T1 - Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer JF - In Vivo JO - In Vivo SP - 909 LP - 916 VL - 31 IS - 5 AU - MASARU MORITA AU - AKINORI EGASHIRA AU - YU NAKAJI AU - MASAKI KAGAWA AU - MASAHIKO SUGIYAMA AU - DAISUKE YOSHIDA AU - MITSUHIKO OTA AU - MASAHIKO IKEBE AU - MUNEYUKI MASUDA AU - YOJIRO INOUE AU - NAONOBU KUNITAKE AU - YASUSHI TOH Y1 - 2017/09/01 UR - http://iv.iiarjournals.org/content/31/5/909.abstract N2 - Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options. ER -